|
The Metabolic Bone Diseases Unit, headed by Professor Sophia Ish-Shalom, specializes in treatment of metabolic bone diseases and mineral disorders, including osteoporosis, hyperparathyroidism, hyper- and hypocalcemia, hormone therapy after menopause, vitamin D deficiency, Paget's Disease, fibrous dysplasia, osteogenesis imperfecta, secondary osteoporosis, bone diseases in organ transplant recipients, bone diseases in patients with gastrointestinal tract diseases, regional osteoporosis, pregnancy and lactation associated osteoporosis, malignancy associated metabolic bone disorders (for example, women treated with aromatase inhibitors [Femara, Arimidex] for breast cancer) and osteoporosis in children. The unit also provides consulting services for patients with other endocrine disorders, including thyroid and adrenal disorders, diabetes, and more.
The unit has developed a special program, based on recent clinical findings, for treating severe osteoporosis and fractures, for example, following a hip fracture. In addition, individuals with bone diseases resulting from other diseases or drug therapies are also treated at the Metabolic Bone Diseases Unit.
The unit conducts numerous clinical research projects in the areas of osteoporosis prevention and treatment, and it is recognized for its accomplishments in this field in the international medical community.
The unit has the facilities to perform advanced laboratory tests at reasonable costs, such as bone turnover measurements (CTX, P1NP), which assist in developing treatment strategies in complex case.
|